Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes

TY - JOUR

T1 - Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes

AU - Hemmingsen, Bianca

AU - Lund, Søren S

AU - Wetterslev, Jørn

AU - Vaag, Allan

N1 - Keywords: Administration, Oral; Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Prevalence; Risk Factors Export Date: 4 November 2009Source: Scopus

PY - 2009

Y1 - 2009

N2 - This article is a narrative review of the current evidence of the effects on cardiovascular disease (CVD) of oral hypoglycaemic agents that increase insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, metformin has been demonstrated to reduce CVD risk, and this beneficial effect may be conserved with the combination of metformin and insulin treatment. However, the effect of glitazones on CVD is uncertain. There is conflicting evidence from large randomized trials to support a protective effect against CVD of lowering blood glucose per se but a systematic review with meta-analysis is lacking. It may be reasonable to aim for an intervention targeting multiple CVD risk factors such as dyslipidaemia, hypertension and albuminuria in T2D patients.

AB - This article is a narrative review of the current evidence of the effects on cardiovascular disease (CVD) of oral hypoglycaemic agents that increase insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, metformin has been demonstrated to reduce CVD risk, and this beneficial effect may be conserved with the combination of metformin and insulin treatment. However, the effect of glitazones on CVD is uncertain. There is conflicting evidence from large randomized trials to support a protective effect against CVD of lowering blood glucose per se but a systematic review with meta-analysis is lacking. It may be reasonable to aim for an intervention targeting multiple CVD risk factors such as dyslipidaemia, hypertension and albuminuria in T2D patients.

U2 - 10.1530/EJE-09-0167

DO - 10.1530/EJE-09-0167

M3 - Journal article

C2 - 19369429

SN - 0804-4643

VL - 161

SP - 1

EP - 9

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 1

ER -